<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128085</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3804-I-01</org_study_id>
    <nct_id>NCT04128085</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors</brief_title>
  <official_title>A Phase I, Open-label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended
      dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3804 in
      patients with advanced malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>Subjects appear the following toxic reaction relate to the drug after treatment within 28 days ：III °or above of non-hematological toxicity, IV° hematological toxicity , neutropenia associated with fever.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0, 1, 2, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 168 hours post-dose on single dose; Hour 0 of day 8,day 15,day14,day 22,day 28 on multiple dose and Hour 0, 1, 2, 4, 6, 8, 10, 12, 18, 24 hours post-dose on multiple dose of day 28.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQB3804 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0, 1, 2, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 168 hours post-dose on single dose; Hour 0 of day 8,day 15,day14,day 22,day 28 on multiple dose and Hour 0, 1, 2, 4, 6, 8, 10, 12, 18, 24 hours post-dose on multiple dose of day 28.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3804 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Hour 0, 1, 2, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 168 hours post-dose on single dose; Hour 0 of day 8,day 15,day14,day 22,day 28 on multiple dose and Hour 0, 1, 2, 4, 6, 8, 10, 12, 18, 24 hours post-dose on multiple dose of day 28.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3804 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>Percentage of participants achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>TQB3804</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3804 tablet administered orally , once daily in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3804</intervention_name>
    <description>A kind of tyrosine kinase inhibitor.</description>
    <arm_group_label>TQB3804</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. Understood and signed an informed consent form. 2. 18 and 70 years old. 3.
        Histologically or cytologically confirmed advanced malignant tumor. 4. Has EGFR mutations.
        5. Life expectancy ≥12 weeks. 6. Eastern Cooperative Oncology Group (ECOG) performance
        status score of 0 to 2.

        7.Adequate organ system function. 8.At least one measurable lesion.

        Exclusion Criteria:

          -  1.Hypersensitivity to TQB3804 or its excipient. 2. Has diagnosed and/or treated
             additional malignancy within 5 years with the exception of cured carcinoma in situ of
             the cervix、intramucosal carcinoma of gastrointestinal tract、breast and non-melanoma
             skin cancers and superficial bladder tumors.

             3.Has interstitial pneumonia. 4.Brain metastases with symptom . 5.Has currently
             uncontrollable congestive heart failure. 6.Has history of arterial thromboembolism
             within 6 months. 7.Has any bleeding tendency or coagulopathy within 6 months. 8.Has
             skin toxicity ≥ grade 2 within 4 weeks. 9.Has serious gastrointestinal diseases within
             4 weeks. 10.Has received any major surgery within 4 weeks. 11.Participated in other
             clinical trials within 4 weeks. 12.Has active viral, bacterial and fungal infections
             within 4 weeks. 13.Has received any cancer therapy within 4 weeks or 5 times of t1/2.
             14.Has ≥ grade 2 toxicity caused by previous anti-tumor treatment. 15. HBsAg positive
             and HBV DNA positive (≥ULN);HCV antibody and HCV-RNA positive (≥ULN); HIV positive or
             ≥HIV ULN.

             16. Has multiple factors affecting oral medication. 17. Breastfeeding or pregnant
             women.; Men unwilling to use adequate contraceptive measures during the study.

             18. According to the judgement of the researchers, there are other factors that
             subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu yilong, Doctor</last_name>
    <phone>020-83877557</phone>
    <email>syylwu@live.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu yilong, Doctor</last_name>
      <phone>020-83877557</phone>
      <email>syylwu@live.cn</email>
    </contact>
    <investigator>
      <last_name>Wu yilong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

